Cannabis and Glaucoma
Cannabis lowers intraocular pressure temporarily but cannot replace standard glaucoma therapy.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
Cannabis does lower eye pressure — that's real and replicated science. But it lasts 3–4 hours, and glaucoma needs 24-hour control. Smoking constantly to manage it is impractical, cognitively costly, and inferior to drops you use once daily. If a long-acting cannabinoid ever gets engineered for the eye, that's a different story. Until then, cannabis is not a glaucoma treatment.
Not medical advice
This article is informational, not medical advice. Glaucoma is a leading cause of irreversible blindness. If you have glaucoma or suspect you do, work with an ophthalmologist. Do not substitute cannabis for prescribed eye drops, laser treatment, or surgery. Stopping standard glaucoma therapy can cause permanent vision loss within months.
What is glaucoma?
Glaucoma is a group of eye diseases characterized by damage to the optic nerve, usually (but not always) associated with elevated intraocular pressure (IOP). Lowering IOP is the only established treatment shown to slow vision loss Strong evidence [1].
In the 1970s, researchers observed that cannabis smokers had measurably lower IOP — roughly 25–30% — but the effect lasted only 3 to 4 hours Strong evidence [2][3]. This discovery sparked decades of speculation that cannabis could treat glaucoma. It does lower pressure; the problem is duration and practicality.
What the evidence shows
IOP reduction is real
The short-term pressure-lowering effect is firmly established:
- Smoked cannabis reduces IOP by 25–30% for 3–4 hours Strong evidence [2][3].
- Oral or sublingual THC produces similar transient reductions Strong evidence [4].
- Intravenous THC confirms the effect is systemic and mediated through CB1 receptors Strong evidence [3].
CBD does not help — and may worsen pressure
A 2006 randomized controlled trial found that a single sublingual dose of CBD slightly raised intraocular pressure, while THC lowered it Strong evidence [8]. CBD is not useful for glaucoma and may be counterproductive.
No evidence of long-term vision preservation
No clinical trial has ever shown that cannabis use preserves vision in glaucoma over months or years. This is not oversight; the 3–4 hour duration makes it implausible. To match a once-daily prostaglandin drop, a person would need to be intoxicated nearly around the clock — a strategy with obvious cognitive, occupational, and safety costs No data.
Experimental approaches with weak or no evidence
- Long-acting cannabinoid analogs. Researchers have explored CB1 agonists with longer half-lives or better eye penetration, but none has reached clinical approval Weak / limited [5].
- Topical cannabinoid eye drops. Cannabinoids are extremely lipophilic and dissolve poorly in the tear film. Early formulations either failed to penetrate or caused ocular irritation Weak / limited [6].
- Neuroprotection independent of IOP. Animal studies suggest cannabinoid receptor activation may shield retinal ganglion cells from excitotoxicity, but human evidence does not exist Weak / limited [7].
- Minor cannabinoids (THCV, CBG, CBN). Preclinical data on their effects on IOP are thin and inconsistent No data.
How cannabis compares to standard treatments
Modern glaucoma care offers multiple effective options, all of which outperform cannabis on clinically relevant measures:
| Treatment | IOP reduction | Duration | Notes |
|---|---|---|---|
| Prostaglandin analogs (latanoprost, bimatoprost, travoprost) | 25–33% | 24+ hours | First-line; once-daily instillation [1] |
| Topical beta-blockers (timolol) | 20–25% | 12 hours | Cost-effective, widely used |
| Topical carbonic anhydrase inhibitors (dorzolamide, brinzolamide) | 15–20% | 8–12 hours | Effective, fewer systemic effects |
| Selective laser trabeculoplasty (SLT) | 20–30% | Years; retreatable | Now often first-line [9] |
| Surgical trabeculectomy or MIGS | Variable; typically large | Permanent or long-term | Reserved for refractory glaucoma |
| Smoked cannabis | 25–30% | 3–4 hours | Requires intoxication; impractical [2][3] |
The core challenge is simple math: you need 24-hour coverage, and cannabis provides 3–4 hours. This is why the American Glaucoma Society and other professional bodies recommend against cannabis for glaucoma [10].
Risks and side effects
- Reduced ocular perfusion pressure. Cannabis lowers systemic blood pressure. In glaucoma, reduced blood flow to the optic nerve may worsen ischemic damage, potentially offsetting any IOP benefit Weak / limited [10].
- Cognitive impairment and driving risk. Maintaining therapeutic intoxication for years carries real occupational and safety costs.
- Pulmonary effects from smoking.
- Dependence. Approximately 9–10% of regular cannabis users develop cannabis use disorder Strong evidence [11].
- Drug interactions. THC and CBD inhibit CYP450 enzymes and interact with systemic glaucoma medications and many other drugs Strong evidence. See Cannabis and Polypharmacy Risks for details.
- Abandonment of proven therapy. The single greatest clinical risk in this area is patients stopping effective eye drops or deferring laser/surgical treatment in favor of cannabis. This causes irreversible blindness Strong evidence.
- Individual variability in pharmaceutical response. Some people respond better to certain eye drops than others. Modern glaucoma management is increasingly individualized, tailoring therapy to each patient's IOP response and tolerance profile. Cannabis does not integrate into this framework.
What we don't know
- Whether engineered long-acting cannabinoid compounds could ever rival prostaglandin analogs.
- Whether cannabinoids provide optic nerve protection independent of IOP reduction in humans.
- Whether chronic heavy cannabis use alters the natural history of glaucoma over decades (no long-term cohort data exist).
- Whether topical cannabinoid formulations can be developed with sufficient penetration and tolerability.
Bottom line
Cannabis lowers intraocular pressure. That fact is replicated and uncontroversial. It is also clinically useless for glaucoma because the effect is too brief, the practicality is too poor, and far better drugs exist. If a long-acting cannabinoid therapeutic ever becomes viable, it will be an engineered molecule delivered directly to the eye — not a smoked or eaten product.
Sources
- Peer-reviewed Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901–1911.
- Peer-reviewed Hepler RS, Frank IR. Marihuana smoking and intraocular pressure. JAMA. 1971;217(10):1392.
- Peer-reviewed Merritt JC, Crawford WJ, Alexander PC, et al. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology. 1980;87(3):222–228.
- Peer-reviewed Flach AJ. Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. Trans Am Ophthalmol Soc. 2002;100:215–222.
- Peer-reviewed Tomida I, Pertwee RG, Azuara-Blanco A. Cannabinoids and glaucoma. Br J Ophthalmol. 2004;88(5):708–713.
- Peer-reviewed Jay WM, Green K. Multiple-drop study of topically applied 1% delta 9-tetrahydrocannabinol in human eyes. Arch Ophthalmol. 1983;101(4):591–593.
- Peer-reviewed Nucci C, Bari M, Spano A, et al. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection. Prog Brain Res. 2008;173:451–464.
- Peer-reviewed Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma. 2006;15(5):349–353.
- Peer-reviewed Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393(10180):1505–1516.
- Practitioner Jampel H. American Glaucoma Society position statement: Marijuana and the treatment of glaucoma. J Glaucoma. 2010;19(2):75–76.
- Government National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: National Academies Press; 2017.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Cognitive Decline — Evidence on cannabis, memory loss, and dementia risk in adults and older people.
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Cannabis Hyperemesis Syndrome (CHS) — Severe cyclic vomiting triggered by chronic heavy cannabis use; resolves on cessation.